Sofgen Pharma S.A. (PROCF)
OTCMKTS
· Delayed Price · Currency is USD
0.0251
0.00 (0.00%)
At close: Apr 22, 2026
Sofgen Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 |
| Revenue | 373.8 | 423.75 | 403.2 | 403.74 | 331.47 | Upgrade
|
| Revenue Growth (YoY) | -11.79% | 5.10% | -0.13% | 21.80% | 2.05% | Upgrade
|
| Cost of Revenue | 182.32 | 185.77 | 168.08 | 174.14 | 140.15 | Upgrade
|
| Gross Profit | 191.48 | 237.98 | 235.13 | 229.6 | 191.31 | Upgrade
|
| Selling, General & Admin | 223.05 | 193.35 | 197.69 | 163.67 | 128.26 | Upgrade
|
| Other Operating Expenses | -3.1 | -16.61 | 3.32 | 74.99 | - | Upgrade
|
| Operating Expenses | 219.96 | 176.74 | 201.01 | 238.67 | 128.26 | Upgrade
|
| Operating Income | -28.48 | 61.24 | 34.11 | -9.07 | 63.05 | Upgrade
|
| Interest Expense | -42.48 | -40.85 | -25.85 | -85.58 | -52.63 | Upgrade
|
| Interest & Investment Income | 0.2 | 0.66 | 0.1 | 0.06 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -17.83 | 24.37 | -18.28 | -5.99 | -3.91 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.97 | 2.88 | 1.88 | 2.18 | -5.67 | Upgrade
|
| EBT Excluding Unusual Items | -89.55 | 48.3 | -8.04 | -98.41 | 0.85 | Upgrade
|
| Impairment of Goodwill | - | -5.79 | -0.84 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 12.65 | 11.19 | 61.8 | 4.51 | - | Upgrade
|
| Asset Writedown | -7.68 | -7.73 | -5.18 | - | - | Upgrade
|
| Pretax Income | -84.59 | 45.96 | 47.74 | -93.9 | 0.85 | Upgrade
|
| Income Tax Expense | -16.29 | 5.62 | 11.61 | 13.09 | 11.3 | Upgrade
|
| Earnings From Continuing Operations | -68.3 | 40.34 | 36.13 | -106.99 | -10.45 | Upgrade
|
| Net Income | -68.3 | 40.34 | 36.13 | -106.99 | -10.45 | Upgrade
|
| Net Income to Common | -68.3 | 40.34 | 36.13 | -106.99 | -10.45 | Upgrade
|
| Net Income Growth | - | 11.67% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 100 | 101 | 101 | 98 | 97 | Upgrade
|
| Shares Outstanding (Diluted) | 100 | 101 | 101 | 98 | 97 | Upgrade
|
| Shares Change (YoY) | -0.73% | -0.10% | 3.02% | 1.04% | - | Upgrade
|
| EPS (Basic) | -0.68 | 0.40 | 0.36 | -1.09 | -0.11 | Upgrade
|
| EPS (Diluted) | -0.68 | 0.40 | 0.36 | -1.09 | -0.11 | Upgrade
|
| EPS Growth | - | 11.79% | - | - | - | Upgrade
|
| Free Cash Flow | 69.05 | 87.3 | -7.61 | 20.02 | 63.22 | Upgrade
|
| Free Cash Flow Per Share | 0.69 | 0.86 | -0.07 | 0.20 | 0.65 | Upgrade
|
| Gross Margin | 51.23% | 56.16% | 58.31% | 56.87% | 57.72% | Upgrade
|
| Operating Margin | -7.62% | 14.45% | 8.46% | -2.25% | 19.02% | Upgrade
|
| Profit Margin | -18.27% | 9.52% | 8.96% | -26.50% | -3.15% | Upgrade
|
| Free Cash Flow Margin | 18.47% | 20.60% | -1.89% | 4.96% | 19.07% | Upgrade
|
| EBITDA | -19.13 | 69.74 | 44.7 | 1.82 | 74.93 | Upgrade
|
| EBITDA Margin | -5.12% | 16.46% | 11.09% | 0.45% | 22.61% | Upgrade
|
| D&A For EBITDA | 9.35 | 8.5 | 10.59 | 10.89 | 11.88 | Upgrade
|
| EBIT | -28.48 | 61.24 | 34.11 | -9.07 | 63.05 | Upgrade
|
| EBIT Margin | -7.62% | 14.45% | 8.46% | -2.25% | 19.02% | Upgrade
|
| Effective Tax Rate | - | 12.22% | 24.33% | - | 1330.51% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.